AR057136A1 - Derivados de indol-3-il-carbonil-azaespiro - Google Patents
Derivados de indol-3-il-carbonil-azaespiroInfo
- Publication number
- AR057136A1 AR057136A1 ARP060104192A ARP060104192A AR057136A1 AR 057136 A1 AR057136 A1 AR 057136A1 AR P060104192 A ARP060104192 A AR P060104192A AR P060104192 A ARP060104192 A AR P060104192A AR 057136 A1 AR057136 A1 AR 057136A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- nririi
- halogen
- links
- Prior art date
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 19
- 229910052736 halogen Inorganic materials 0.000 abstract 9
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 5
- 125000005843 halogen group Chemical group 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 2
- 125000001041 indolyl group Chemical group 0.000 abstract 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010007558 Cardiac failure chronic Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000005171 Dysmenorrhea Diseases 0.000 abstract 1
- 206010013935 Dysmenorrhoea Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010053198 Inappropriate antidiuretic hormone secretion Diseases 0.000 abstract 1
- 206010029164 Nephrotic syndrome Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
REIVINDICACIoN 1.- Un compuesto de la siguiente formula general (1): en la que R1 es H, alquilo C1-6, arilo, heteroarilo de 5 o 6 eslabones o sulfonilarilo, cada uno de los cuales está opcionalmente sustituido por uno o varios B, -(CH2)m-Ra, en el que Ra es: CN, OR1, NRiRii, cicloalquilo C3-6, heterocicloalquilo de 4 a 7 eslabones, arilo o heteroarilo de 5 a 6 eslabones, cada uno de los cuales está opcionalmente sustituido por uno o varios B, -CH2)n-(CO-Rb o -(CH2)n-(SO2)-Rb, en los que Rb es: alquilo C1-6, alcoxi C1-6, cicloalquilo C3-6, -(CH2)m-NRiiiRiv, NRiRii, cicloalquilo C3-6, heterocicloalquilo de 4 a 7 eslabones, arilo o heteroarilo de 5 o 6 eslabones, cada uno de los cuales está opcionalmente sustituido por uno o varios B, o R1 y R3 junto con el anillo indol al que están unidos forman un heterocicloalquilo de 5 o 6 eslabones que está opcionalmente sustituido por = O; hay uno o varios R2, cada R2 segun su aparicion es igual o diferente, R2 es uno o varios H, OH, halogeno, CN, nitro, alquilo C1-6 opcionalmente sustituído por -NRiiiRiv, alcoxi C1-6, -O-CH2-alquenilo C2-6 o benciloxi, o dos R2 junto con el anillo indol al que están unidos forman un puente oxo o dioxo; R3 es H, halogeno, -(CO)-Rc, en el que Rc es: alquilo C1-6, -(CH2)n-NRiRii, -(CH2)n-NRiiiRiv o heterocicloalquilo de 5 o 6 eslabones opcionalmentesustituido por alquilo C1-6, o alquilo C1-6 o arilo, cada uno de los cuales está opcionalmente sustituido por halogeno, -O(CO)-alquilo C1-6 o - NH(CO)Rd, en el que Rd es alquilo C1-6 opcionalmente sustituido por halogeno o nitro, o Rd es arilo o a heteroarilo de 5 o 6 eslabones, cada uno de los cuales está opcionalmente sustituido por halogeno, nitro, alquilo C1-6 o haloalquilo C1-6; B es halogeno, CN, NRiRii, alquilo C1-6 opcionalmente sustituido por CN, halogeno o alcoxi C1-6, alcoxi C1-6, haloalcoxi C1-6, cicloalquilo C3-6, -C(O) O-alquilo C1-6, -C(O) NRiRii, -C(O)-alquilo C1-6, -S(O)2-alquilo C1-6, -S(O)2-, NRiRii o (CRiiiRiv)n- heteroarilo de 5 o 6 eslabones, en el que el resto fenilo o heteroarilo de 5 o 6 eslabones está opcionalmente sustituido por uno o varios sustituyentes, elegidos entre el grupo formado por: halogeno, CN, NRiRii, alquilo C1-6 opcionalmente sustituido por CN o alcoxi C1-6, alcoxi C1-6, haloalcoxi C1-6, cicloalquilo C3-6, -C(O)O-alquilo C1-6, -C(O)-NRiRii, -C(O)-alquilo C1-6, -S(O)2-alquilo C1-6 y -S(O)2- NRiRii; Ri y Rii con independencia entre sí con H, alquilo C1-6, (alquil C1-6)-NRiiiRiv, - (CO)O-alquilo C1-6, -C(O)-NRiiiRiv, -C(O)-alquilo C1-6, -S(O)2-alquilo C1-6 o -S(O)2- NRiiiRiv; Riii y Riv con independencia entre sí son H o alquilo C1-6; m es un numero de 1 a 6; n es un numero de 0 a 4; A es un grupo de la formula (a) o de la (b): en las que R4 es H o alquilo C1-6; R5 es arilo opcionalmente sustituido por halogeno; o una sal farmacéuticamente aceptable de los mismos. Se refiere además a composiciones farmacéuticas que contienen estos compuestos, a su utilizacion en medicamentos contra la dismenorrea, la hipertension, el fallo cardíaco cronico, la secrecion inapropiada de vasopresina, la cirrosis hepática, el síndrome nefrotico, el trastorno obsesivo-compulsivo, la ansiedad y los trastornos depresivos, y a métodos para la obtencion de dichos compuestos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05108966 | 2005-09-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR057136A1 true AR057136A1 (es) | 2007-11-21 |
Family
ID=37156049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060104192A AR057136A1 (es) | 2005-09-28 | 2006-09-26 | Derivados de indol-3-il-carbonil-azaespiro |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7790752B2 (es) |
| EP (1) | EP1931680B1 (es) |
| JP (1) | JP4908513B2 (es) |
| KR (1) | KR101018934B1 (es) |
| CN (1) | CN101273046B (es) |
| AR (1) | AR057136A1 (es) |
| AT (1) | ATE488519T1 (es) |
| AU (1) | AU2006298828B2 (es) |
| BR (1) | BRPI0616618A2 (es) |
| CA (1) | CA2623715A1 (es) |
| DE (1) | DE602006018334D1 (es) |
| ES (1) | ES2354909T3 (es) |
| IL (1) | IL189981A (es) |
| RU (1) | RU2418801C2 (es) |
| TW (1) | TWI327571B (es) |
| WO (1) | WO2007039438A1 (es) |
| ZA (1) | ZA200802339B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070072795A1 (en) * | 2005-09-28 | 2007-03-29 | Anton Haselbeck | Treatment of neurodegenerative disorders |
| ES2345132T3 (es) | 2006-12-08 | 2010-09-15 | F. Hoffmann-La Roche Ag | Indoles que actuan como agonistas del receptor v1a. |
| CN101838269B (zh) * | 2009-03-18 | 2012-09-26 | 中国人民解放军军事医学科学院毒物药物研究所 | 1,3,8-三氮杂-螺[4.5]癸烷-4-酮类化合物及其医药用途 |
| JO3109B1 (ar) * | 2012-05-10 | 2017-09-20 | Ferring Bv | منبهات لمستقبلات v1a |
| WO2017005583A1 (en) * | 2015-07-03 | 2017-01-12 | F. Hoffmann-La Roche Ag | Triaza-spirodecanones as ddr1 inhibitors |
| EP3414247B1 (en) | 2016-02-08 | 2021-04-21 | F. Hoffmann-La Roche AG | Spiroindolinones as ddr1 inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2769578B2 (ja) * | 1989-10-13 | 1998-06-25 | 大塚製薬株式会社 | バソプレシン拮抗剤 |
| JP2002515891A (ja) * | 1997-12-19 | 2002-05-28 | スミスクライン・ビーチャム・コーポレイション | 新規なピペリジン含有化合物 |
| HU225703B1 (en) * | 1999-07-15 | 2007-06-28 | Sanofi Aventis | Process for producing spiro[cis-4-(betha-hydroxy-ethyloxi)-cyclohexane-[3h]indole]-2'[1'h]-one derivatives |
| US6150365A (en) * | 1999-08-05 | 2000-11-21 | Bristol-Myers Squibb Company | Anxiety method |
| EP1601674B1 (en) * | 2002-09-09 | 2012-08-08 | Janssen Pharmaceutica NV | Hydroxyalkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders |
| ZA200510329B (en) * | 2003-05-23 | 2007-04-25 | Zealand Pharma As | Triaza-spiro compounds as nociceptin analogues and uses thereof |
| US7745630B2 (en) * | 2003-12-22 | 2010-06-29 | Justin Stephen Bryans | Triazolyl piperidine arginine vasopressin receptor modulators |
| DE602006004997D1 (de) * | 2005-07-14 | 2009-03-12 | Hoffmann La Roche | Indol-3-carbonyl-spiro-piperidinderivate als antagonisten des v1a-rezeptors |
| US7351706B2 (en) * | 2006-01-05 | 2008-04-01 | Hoffmann-La Roche Inc. | Indol-3-yl-carbonyl-spiro-piperidine derivatives |
| WO2008068159A1 (en) * | 2006-12-07 | 2008-06-12 | F. Hoffmann-La Roche Ag | Spiro-piperidine derivatives |
-
2006
- 2006-09-18 CN CN2006800358570A patent/CN101273046B/zh not_active Expired - Fee Related
- 2006-09-18 EP EP06793584A patent/EP1931680B1/en not_active Not-in-force
- 2006-09-18 AT AT06793584T patent/ATE488519T1/de active
- 2006-09-18 ES ES06793584T patent/ES2354909T3/es active Active
- 2006-09-18 AU AU2006298828A patent/AU2006298828B2/en not_active Ceased
- 2006-09-18 WO PCT/EP2006/066441 patent/WO2007039438A1/en not_active Ceased
- 2006-09-18 KR KR1020087007377A patent/KR101018934B1/ko not_active Expired - Fee Related
- 2006-09-18 BR BRPI0616618-0A patent/BRPI0616618A2/pt not_active IP Right Cessation
- 2006-09-18 RU RU2008110409/04A patent/RU2418801C2/ru not_active IP Right Cessation
- 2006-09-18 JP JP2008532722A patent/JP4908513B2/ja not_active Expired - Fee Related
- 2006-09-18 CA CA002623715A patent/CA2623715A1/en not_active Abandoned
- 2006-09-18 DE DE602006018334T patent/DE602006018334D1/de active Active
- 2006-09-21 US US11/524,978 patent/US7790752B2/en not_active Expired - Fee Related
- 2006-09-25 TW TW095135364A patent/TWI327571B/zh not_active IP Right Cessation
- 2006-09-26 AR ARP060104192A patent/AR057136A1/es unknown
-
2008
- 2008-03-06 IL IL189981A patent/IL189981A/en not_active IP Right Cessation
- 2008-03-12 ZA ZA200802339A patent/ZA200802339B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL189981A (en) | 2012-09-24 |
| EP1931680A1 (en) | 2008-06-18 |
| CA2623715A1 (en) | 2007-04-12 |
| DE602006018334D1 (de) | 2010-12-30 |
| AU2006298828A1 (en) | 2007-04-12 |
| RU2008110409A (ru) | 2009-11-10 |
| JP4908513B2 (ja) | 2012-04-04 |
| AU2006298828B2 (en) | 2011-12-01 |
| JP2009510010A (ja) | 2009-03-12 |
| KR101018934B1 (ko) | 2011-03-02 |
| BRPI0616618A2 (pt) | 2011-06-28 |
| TW200804392A (en) | 2008-01-16 |
| US20070072888A1 (en) | 2007-03-29 |
| KR20080049780A (ko) | 2008-06-04 |
| CN101273046B (zh) | 2011-05-25 |
| ES2354909T3 (es) | 2011-03-21 |
| IL189981A0 (en) | 2008-08-07 |
| ZA200802339B (en) | 2009-10-28 |
| EP1931680B1 (en) | 2010-11-17 |
| RU2418801C2 (ru) | 2011-05-20 |
| CN101273046A (zh) | 2008-09-24 |
| US7790752B2 (en) | 2010-09-07 |
| ATE488519T1 (de) | 2010-12-15 |
| TWI327571B (en) | 2010-07-21 |
| WO2007039438A1 (en) | 2007-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR059136A1 (es) | Derivados de indol-3-il-carbonil-espiro-piperidina | |
| AR057086A1 (es) | Derivados de indol-3- il-carbonil-piperidina y piperazina, composicion farmaceutica y proceso de preparacion del compuesto | |
| AR046758A1 (es) | Inhibidores de la ns3/ns4a serina proteasa del virus de la hepatitis c | |
| AR053774A1 (es) | Derivados de sulfonilbencimidazol. composiciones farmaceuticas. | |
| AR040080A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR063331A1 (es) | Derivados de biaril eter urea y composiciones farmaceuticas | |
| AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
| AR069523A1 (es) | Derivados de isoxazolo - piridina | |
| AR044614A1 (es) | Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4) | |
| AR053306A1 (es) | Derivados de pirazolopiridina. procesos de obtencion y composiciones farmaceuticas. | |
| AR037676A1 (es) | Inhibidores del factor xa y de otras proteasas de serina implicadas en la cascada de la coagulacion; composicion farmaceutica que los comprende y procedimiento para preparar compuestos de formula (i) | |
| EA200400113A1 (ru) | Ингибиторы вирусной полимеразы | |
| CO6160234A2 (es) | Nuevos compuestos ciclicos fusionados que presentan una accion moduladora de la funcion del recptor gpr40 | |
| AR048413A1 (es) | Compuestos prolina 3,4- (ciclopentil) - fusionados , como inhibidores de serina proteasa ns3 del virus de la hepatitis c | |
| AR039124A1 (es) | Derivados de adamantano, procedimiento de preparacion y composiciones farmaceuticas que los contienen | |
| AR051092A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa | |
| AR056195A1 (es) | Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos | |
| AR037352A1 (es) | Compuestos ligandos de los receptores de los cannabinoides, una composicion farmaceutica , y el uso de dichos compuestos para la manufactura de medicamentos | |
| AR046422A1 (es) | Acidos carboxilicos macrociclicos y acilsulfonamidas como inhibidores de la replicacion del vhc | |
| AR082696A1 (es) | Derivados heterociclicos nitrogenados de 1,2,4-oxadiazol, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades cardiovasculares e inflamatorias, entre otras | |
| AR054830A1 (es) | Derivados de indol -3-il-espiro-piperidina como antagonista del receptor v1a | |
| AR074354A1 (es) | Alquilciclohexileteres de dihidrotetraazabenzoazulenos, procesos de preparacion y composiciones farmaceuticas que los contienen | |
| AR068376A1 (es) | Amidas heterociclicas utiles para inhibir la via hedgehog. | |
| AR051995A1 (es) | Derivados de tieno-piridina como intensificadores alostericos de gaba -b | |
| AR046992A1 (es) | Derivados de espiro-dihidrobenzofuranos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |